Balaxi Pharmaceuticals Limited (NSE:BALAXI)
India flag India · Delayed Price · Currency is INR
32.48
-1.62 (-4.75%)
Dec 8, 2025, 1:48 PM IST

Balaxi Pharmaceuticals Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 20212016 - 2020
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2016 - 2020
1,8833,2545,0495,3873,5165,245
Upgrade
Market Cap Growth
-52.71%-35.56%-6.27%53.22%-32.97%608.78%
Upgrade
Enterprise Value
2,0592,9664,9555,3053,4915,213
Upgrade
Last Close Price
34.1063.9299.19106.0770.23104.76
Upgrade
PE Ratio
13.0312.98-11.727.3813.75
Upgrade
PS Ratio
0.681.112.091.601.262.27
Upgrade
PB Ratio
0.791.402.512.953.118.07
Upgrade
P/TBV Ratio
0.911.592.883.423.918.23
Upgrade
P/FCF Ratio
--120.99-12.20-
Upgrade
P/OCF Ratio
--103.7788.6710.30169193.55
Upgrade
EV/Sales Ratio
0.741.012.051.581.252.25
Upgrade
EV/EBITDA Ratio
9.428.0110.609.386.9512.24
Upgrade
EV/EBIT Ratio
10.318.4011.109.687.0212.33
Upgrade
EV/FCF Ratio
-5.70-118.73-12.11-
Upgrade
Debt / Equity Ratio
0.240.230.100.070.030.06
Upgrade
Debt / EBITDA Ratio
2.591.440.420.240.070.09
Upgrade
Debt / FCF Ratio
--4.65-0.13-
Upgrade
Asset Turnover
0.911.030.971.622.023.41
Upgrade
Inventory Turnover
1.872.071.382.033.5323.92
Upgrade
Quick Ratio
2.462.812.211.540.582.28
Upgrade
Current Ratio
3.964.453.883.642.232.70
Upgrade
Return on Equity (ROE)
6.39%11.58%-1.24%31.05%53.51%82.26%
Upgrade
Return on Assets (ROA)
4.09%7.76%11.21%16.46%22.51%38.97%
Upgrade
Return on Capital (ROIC)
4.60%8.73%13.38%21.89%33.52%54.85%
Upgrade
Return on Capital Employed (ROCE)
7.60%13.80%21.90%29.40%43.90%65.10%
Upgrade
Earnings Yield
7.70%7.70%-0.47%8.53%13.55%7.27%
Upgrade
FCF Yield
-19.20%-17.25%0.83%-1.30%8.20%-0.24%
Upgrade
Dividend Yield
----0.14%-
Upgrade
Payout Ratio
---1.08%--
Upgrade
Buyback Yield / Dilution
-3.60%-7.26%-1.69%-1.23%--32.96%
Upgrade
Total Shareholder Return
-3.60%-7.26%-1.69%-1.23%0.14%-32.96%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.